Welcome to LookChem.com Sign In|Join Free
  • or
Carbamic acid, [4-[[1,4-dihydro-1,4-dioxo-3-(1-pyrrolidinyl)-2-naphthalenyl]amino]phenyl ]-, 1,1-dimethylethyl ester is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

465547-29-9

Post Buying Request

465547-29-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

465547-29-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 465547-29-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,6,5,5,4 and 7 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 465547-29:
(8*4)+(7*6)+(6*5)+(5*5)+(4*4)+(3*7)+(2*2)+(1*9)=179
179 % 10 = 9
So 465547-29-9 is a valid CAS Registry Number.

465547-29-9Downstream Products

465547-29-9Relevant academic research and scientific papers

Identification of compounds for the treatment or prevention of proliferative diseases

-

Page 19, (2010/02/03)

The invention features compounds for the treatment of cancer and other proliferative diseases. These compounds were identified in screening assays that contact candidate compounds with a cell containing a nucleic acid that includes a HER2 regulatory element and a reporter sequence. The invention further features compounds structurally related to those identified by the screening assays. Finally, the invention features methods of treating or preventing a proliferative disease using the compounds of the invention.

Identification of compounds for the treatment or prevention of proliferative diseases

-

, (2008/06/13)

The invention features screening assays for compounds that are potentially useful for treating or preventing a proliferative disease. The assays are based on contacting a candidate compound with a cell containing a nucleic acid including a HER2 regulatory element and a reporter sequence. In addition, the invention features compounds identified by the assays of the invention. The invention further features compounds structurally related to those identified by the screening assays. Finally, the invention features methods of treating or preventing a proliferative disease using the compounds of the invention.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 465547-29-9